When was Anelixis Therapeutics founded?

Anelixis Therapeutics was founded in 2013 and raised its 1st funding round 4 years after it was founded.

Where is Anelixis Therapeutics located?

Anelixis Therapeutics is headquartered in Cambridge, United States.

Who is the current CEO of Anelixis Therapeutics?

David-Alexandre C Gros of Anelixis Therapeutics. They have also founded 1 company.

Is Anelixis Therapeutics a funded company?

Anelixis Therapeutics is a funded company, having raised a total of $12.9M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jun 20, 2017.

When was the latest funding round of Anelixis Therapeutics?

Anelixis Therapeutics' latest funding was a $***** Series B round on Jan 2020, with participation from 0 investor. Its primary sector is Neurology. In United States, the Neurology sector has seen $4.05B in funding in 2026 to date.

Where does Anelixis Therapeutics rank among its competitors?

Anelixis Therapeutics ranks 411th amongst 587 active competitors, of which 190 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was MapLight, which secured $150M in Aug, 2026.

Who are the top competitors of Anelixis Therapeutics?

Anelixis Therapeutics' top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, MapLight secured the most recent funding round in August, 2026.

Anelixis Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Anelixis Therapeutics is an acqui-hired company based in Cambridge (United States), founded in 2013. It operates as a Developing CD40 & SOD1 targeting drugs for ALS. Anelixis Therapeutics has raised $12.9M in funding from BVF Partners. The company has 587 active competitors, including 190 funded and 132 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Biogen and PTC Therapeutics.

Company Details

Anelixis Therapeutics, a subsidiary of ALS Therapy Development Institute (ALS TDI), is focussed on developing drugs for Amyotrophic lateral sclerosis (ALS). It currently has 2 clinical programs targeting the CD40, Tumor Necrosis Factor (TNF) and superoxide dismutase (SOD1) which play a role in the pathogenesis of ALS. In addition to the clinical assets, it has issued patents for the method of treatment of neurodegenerative diseases by targeting CD40 and the targeting of CD8+ T-Lymphocytes to treat neurodegenerative diseases.

Website: anelixistherapeutics.com
Part Of

Key Metrics

Founded Year

2013

Location

Cambridge, United States

Stage

Acqui-Hired

Total Funding

$12.9M in 5 rounds

Latest Funding Round

Series B, Jan 2020, $*****

Investors

BVF Partners

Ranked

411^th among 587 active competitors

Similar Companies

Keros Therapeutics & 107 more

View Anelixis Therapeutics' full profile

Anelixis Therapeutics has raised a total funding of $12.9M over 5 rounds. Its first funding round was on Jun 20, 2017. Anelixis Therapeutics has 1 institutional investor.

Here is the list of recent funding rounds of Anelixis Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 2020	2278039	Series B	3431643	9778021	6802274	3524175
Nov 18, 2019	3796948	Series B	9866817	3682568	3478171	5538307
May 15, 2019	3926787	Conventional Debt	2909204	2809777	8379274	7092128

Access funding benchmarks and valuations. Sign up today!

View details of Anelixis Therapeutics's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Anelixis Therapeutics include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Anelixis Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Pacira 2006, Parsippany Troy Hills (United States), Public	Developer of injectable non-opioid products for post-surgical pain control	$85M	Orbimed, HBM Healthcare Investments & 6 others	69/100
5th	AskBio 2001, Durham (United States), Acquired	Developer of AAV technologies for treating genetic and complex disorders	$235M	Vida Ventures, TPG & 4 others	68/100
6th	MapLight 2018, Redwood City (United States), Public	Developer of therapeutic for central nervous system disorders	$698M	Goldman Sachs, Cowen & 10 others	68/100
7th	Neurocrine 1992, San Diego (United States), Acquired	Developer of small molecule therapeutics for endocrine and CNS disorders	$10M	Venrock, BB Biotech & 6 others	68/100
8th	Neumora 2020, Watertown (United States), Public	Developer of precision medicines for neuropsychiatric disorders and neurodegenerative disorders	$612M	Arch Venture Partners, Mubadala & 19 others	67/100
9th	Keros Therapeutics 2016, Lexington (United States), Public	Developer of small molecules to treat hematologic and musculoskeletal disorders	$90M	Foresite Capital, Pontifax & 9 others	66/100
10th	Septerna 2020, San Bruno (United States), Public	Developer of GPCR drug discovery platform for multiple diseases	$250M	RA Capital Management, Third Rock Ventures ... & 14 others	66/100
411th	Anelixis Therapeutics 2013, Cambridge (United States), Acqui-Hired	Developing CD40 & SOD1 targeting drugs for ALS	$12.9M	BVF Partners	25/100